Clinical Trials Logo
  1. Home
  2. Macrophage Activation Syndrome
  3. NCT05137496

Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome

Macrophage Activation Syndrome Clinical Trial

Official title:
A Single-center, Prospective, Non-comparative Clinical Trial of Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome

Clinical Trial Summary

The present study was a single-center, prospective, non-comparative in which macrophage activation syndrome patients were selected as the main subjects to evaluate the effect and safety of Ruxolitinib and methylprednisolone regimens as the first-line therapy .

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05137496
Study type Interventional
Source Beijing Friendship Hospital
Contact Yue Song
Phone 86-010-63139862
Email xueqifeng1992@163.com
Status Not yet recruiting
Phase Phase 3
Start date June 1, 2022
Completion date June 1, 2024
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03721809 - Characterization of the Inflammatory Profile of Patients With Macrophage Activation Syndrome Secondary to Bacterial Sepsis N/A
Recruiting NCT06339177 - Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Active, not recruiting NCT02780583 - Treatment of Macrophage Activation Syndrome (MAS) With Anakinra Phase 1
Active, not recruiting NCT01966367 - CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation Phase 1/Phase 2
Enrolling by invitation NCT01095146 - New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome N/A
Recruiting NCT02569463 - Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS） Phase 1/Phase 2
Active, not recruiting NCT03827343 - Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
Recruiting NCT05611710 - Anakinra in Dengue With Hyperinflammation ( AnaDen ) Phase 2
Completed NCT03311854 - A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH) Phase 2
Recruiting NCT05001737 - Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE Phase 3
Completed NCT03332225 - A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis Phase 2
Completed NCT04339712 - Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction Phase 2